Kidney newco Goldfinch launches with $55M

Third Rock Ventures launched Goldfinch Biopharma Inc. (Cambridge, Mass.) with a $55 million series A round to develop precision therapies for kidney diseases. The firm was the sole investor.

Goldfinch intends to establish a registry of patients' genetic and genomic data, from which it hopes to choose actionable targets that drive disease. The company hopes to test therapeutic candidates for responses using multiple models, including an in vitro system that uses patient-derived induced pluripotent stem cell (iPSC) lines and organoids. Finally, the company would use genetic patient stratification to tailor candidates to patients, SVP of Biology Peter Mundel told BioCentury...